CLIA certification is the federal standard that determines whether a genetic lab can produce results a qualified healthcare provider can actually act on. The Precision Peptide Genetic Test uses Illumina Global Screening Array genotyping at CLIA-certified labs — processing 58 SNPs across 49 genes for 150+ genetic insights. This post explains what CLIA certification requires and why the standard matters.

The Precision Peptide Genetic Test analyzes how your genes relate to the pathways targeted by 49 unique compounds across 14 areas of health, from weight management and GLP-1 biology to muscle growth, longevity, and sleep. This post breaks down what the 49-peptide panel covers and how each pathway maps to your genetics.

Genetic testing reveals tendencies, not outcomes — a FOXO3 variant doesn't predict lifespan, a slow-COMT variant doesn't diagnose any condition, an ACTN3 XX genotype doesn't cap muscle growth. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights. Understanding what DNA can and cannot tell you is the difference between informed and overconfident.

Your Precision Peptide Genetic Test report delivers 150+ insights across 14 pathways, including FOXO3 for longevity, ACTN3 for muscle, and GIPR for weight management. This guide walks through how to read pathway scores, interpret gene variants, and turn findings into the informed conversation every peptide protocol decision should start with.

Before committing to a peptide protocol, genetic testing reveals how your body will actually respond across GLP-1 signaling, growth hormone axis, estrogen clearance, and sexual response pathways. The Precision Peptide Genetic Test maps 14 pathways, 49 peptides, and 150+ genetic insights. Test first. Invest second. That sequence is the entire premise of precision peptide decisions.

The precision health stack is a 4-layer system: genetic testing as the foundation, blood work for state data, supplements and lifestyle for baseline support, and protocols as the intervention layer. The Precision Peptide Genetic Test anchors the stack — analyzing 14 pathways, 49 peptides, and 150+ genetic insights that shape how every layer above performs.

Genetic peptide testing analyzes how your DNA shapes 14 biological pathways that peptide protocols target — from GLP-1 signaling to growth hormone axis to estrogen clearance. The PlexusDx Precision Peptide Genetic Test delivers 150+ insights across 49 unique peptides, turning peptide decisions from guesswork into evidence-based conversations with your healthcare provider.

The Precision Peptide Genetic Test processes raw DNA through Illumina Global Screening Array genotyping, CLIA-certified lab analysis, and AI-driven pathway interpretation — transforming 58 SNPs across 49 genes into 150+ actionable insights spanning 14 pathways and 49 peptides. This post explains how that pipeline works end to end, from saliva sample to personalized genetic report.

The PlexusDx Precision Peptide Genetic Test analyzes 17 longevity-aging genetic insights across five peptide pathways — Epitalon, FOXO4-DRI, Glutathione, Humanin, and Vilon — covering 15 SNPs across 14 genes including FOXO3, TERT, SIRT1, GPX1, and PPARGC1A. This article explains what each insight reveals and why peptide-specific longevity testing is a distinct category of genetic analysis.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including the pathways most relevant to GLP-1 receptor signaling. This article explains what the research shows about genetics and semaglutide response, why MTHFR methylation status matters in the broader metabolic picture, and how genetic testing can help inform a smarter weight management approach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including GLP-1 receptor signaling and GIPR response pathways. This article explains how genes like FTO, MC4R, and PPARG influence appetite, fat metabolism, and weight regulation, and why your DNA may be the most underused variable in any weight management decision.

A Diabetes Care analysis estimates tirzepatide may reduce MACE risk by up to 28% and all-cause mortality by 39% compared to theoretical placebo — a figure the SURPASS-CVOT trial design couldn't directly show. Here's what the imputed placebo data reveals, and why GLP-1 receptor pathway genetics matter before any weight management decision.